Cancer Institute and Hospital Chinese Acedemy of Medical SciencesBeijing, Beijing
Disclosures:
3733 - Neoadjuvant Chemotherapy plus Tislelizumab Followed by Adjuvant Tislelizumab for Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial
Wednesday, October 2, 202410:30 AM – 11:45 AM ET
3734 - Long-Term Treatment Outcomes and Late Toxicity between Childhood and Adult Nasopharyngeal Carcinoma in the Era of IMRT
